RxDoctor Payments Data

Kimberly Charlton, MD

Psychiatry · Los Angeles, CANPI 1447317771

Payments from drug & device makers

$3,334in general payments, 2019–2025

Across 106 payments — averaging $31.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alkermes, Inc.$571
  • Otsuka America Pharmaceutical, Inc.$432
  • Indivior Inc.$399
  • AbbVie$321
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$298
  • Sunovion Pharmaceuticals Inc.$297
  • plus $1K from 5 others

What the payments were for

  • Food & beverage$3,334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,334 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$17,311
Medicare patients
24
Services billed
156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$70,785
CaplytaLumateperone Tosylate15$16,118
Aripiprazole28$709
Hydroxyzine Hcl34$349
Quetiapine Fumarate42$338
Gabapentin27$265
Olanzapine32$253
Buspirone Hcl11$234
Trazodone Hcl42$221
Mirtazapine25$212
Bupropion XlBupropion Hcl16$180
Duloxetine Hcl24$162
Venlafaxine Hcl ErVenlafaxine Hcl17$157
Clonazepam34$131
Sertraline Hcl33$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$192$70,78511 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$298$16,11815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →